School personnel should soon be allowed to administer a new nasal spray used to treat severe hypoglycemia. In 2019, the Food and Drug Administration approved the use of Baqsimi nasal powder, the first ...
Each Baqsimi device includes 1 dose of glucagon and cannot be refused. The Food and Drug Administration (FDA) has expanded the approval of Baqsimi (glucagon) nasal powder to include the treatment of ...
CHICAGO--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology ...
A collaborative intervention model involving a clinical pharmacist significantly reduces severe hypoglycemia risk without compromising glycemic control.
REDWOOD CITY, Calif., May 05, 2025 (GLOBE NEWSWIRE) -- Rezolute, Inc. (RZLT) (Nasdaq: RZLT) (“Rezolute” or the “Company”), a late-stage rare disease company focused on treating hypoglycemia caused by ...
Phase 3 registrational trial for ersodetug in patients with tumor hyperinsulinism (HI) expected to commence in 2025; real-world patient benefit demonstrated in Expanded Access Program REDWOOD CITY, ...
Add Yahoo as a preferred source to see more of our stories on Google. The logo of Lilly is seen on a wall of the Lilly France company unit, part of the Eli Lilly and Co drugmaker group, in Fegersheim ...
Researchers have shown that a targeted treatment they developed is effective at controlling blood sugar in patients with hyperinsulinism (HI), a genetic disease in which the pancreas produces too much ...
Verywell Health on MSN
Dealing with the sugar crash of reactive hypoglycemia after eating
Medically reviewed by Sameena Zahoor, MD Key Takeaways Reactive hypoglycemia is low blood sugar happening within four hours of eating.Symptoms of reactive hypoglycemia include a fast heartbeat, ...
Rezolute (RZLT) announced that the U.S. Food and Drug Administration, FDA, has granted Breakthrough Therapy Designation, BTD, to ersodetug, RZ358, for the treatment of hypoglycemia due to congenital ...
CHICAGO--(BUSINESS WIRE)--Xeris Pharmaceuticals, Inc. (Nasdaq: XERS), a pharmaceutical company leveraging its novel formulation technology platforms to develop and commercialize ready-to-use ...
REDWOOD CITY, Calif., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Rezolute, Inc. (RZLT) (“Rezolute” or the “Company”), a late-stage biopharmaceutical company dedicated to developing transformative therapies for ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results